Astrazeneca-oxford Coronavirus Vaccine

The gap between the first and second doses of the Covishield COVID-19 vaccine can be increased to 12-16 weeks - from the existing six-eight weeks - the government said Thursday, adding that there are no recommended changes in Covaxin dosage interval

The coronavirus vaccine developed in Britain by Oxford University and UK-Swedish pharmaceutical firm AstraZeneca has suffered several setbacks since its development, dampening hopes over its global role in ending the pandemic.

European Commission chief Ursula von der Leyen announced Friday that the AstraZeneca-Oxford University coronavirus vaccine has been authorised for the EU market, hours after the bloc's drug regulator recommended its approval.

Mexico on Monday authorized the coronavirus vaccine developed by AstraZeneca and the University of Oxford for emergency use in the country, which has one of the world's highest Covid-19 death tolls.

Britain on Monday began rolling out the Oxford-AstraZeneca coronavirus vaccine, a possible game-changer in fighting the disease worldwide, while China raced to inoculate millions with a homegrown prophylactic.

The United States is expected to approve the low-cost AstraZeneca/Oxford vaccine in April, a senior official said, more than three months after Britain's green light on Wednesday.

Argentina has followed Britain to become only the second country to authorize the coronavirus vaccine developed by drug firm AstraZeneca and Oxford University, the government said on Wednesday.

Britain on Wednesday became the first country in the world to approve a coronavirus vaccine developed by Oxford University and AstraZeneca as it battles a major winter surge driven by a new, highly contagious variant of the virus.

The gap between the first and second doses of the Covishield COVID-19 vaccine can be increased to 12-16 weeks - from the existing six-eight weeks - the government said Thursday, adding that there are no recommended changes in Covaxin dosage interval

The coronavirus vaccine developed in Britain by Oxford University and UK-Swedish pharmaceutical firm AstraZeneca has suffered several setbacks since its development, dampening hopes over its global role in ending the pandemic.

European Commission chief Ursula von der Leyen announced Friday that the AstraZeneca-Oxford University coronavirus vaccine has been authorised for the EU market, hours after the bloc's drug regulator recommended its approval.

Mexico on Monday authorized the coronavirus vaccine developed by AstraZeneca and the University of Oxford for emergency use in the country, which has one of the world's highest Covid-19 death tolls.

Britain on Monday began rolling out the Oxford-AstraZeneca coronavirus vaccine, a possible game-changer in fighting the disease worldwide, while China raced to inoculate millions with a homegrown prophylactic.

The United States is expected to approve the low-cost AstraZeneca/Oxford vaccine in April, a senior official said, more than three months after Britain's green light on Wednesday.

Argentina has followed Britain to become only the second country to authorize the coronavirus vaccine developed by drug firm AstraZeneca and Oxford University, the government said on Wednesday.

Britain on Wednesday became the first country in the world to approve a coronavirus vaccine developed by Oxford University and AstraZeneca as it battles a major winter surge driven by a new, highly contagious variant of the virus.